In TNBC, where the lack of efficacious targeted therapies contributes to a high rate of relapse, increased metastases, and mortality, aberrant expression of eIF4A1 has been reported to drive the translation of oncogenic mRNAs involved in cancer-related pathways, such as those regulating cell proliferation and survival (cyclins D1/D3, survivin), pluripotency (SOX2, OCT4, NANOG), and chemoresistance [ATP-binding cassette (ABC) drug efflux transporters (ABCB1, ABCC1, and ABCG2), which efflux neoadjuvant chemotherapeutic drugs (NACT) contributing to multidrug resistance] [19, 20]. Here, EIF4A1 is linked to cancer.